Countdown to BIOHK2026: World-Class Biotech Convention Prepares to Host Global Pavilions, Multi-Track Forums, and Signature Executive Networking
HONG KONG, Aug. 27, 2026 /PRNewswire/ -- As a premier global landmark in biotech, BIOHK2026 convenes international biotech hubs, cross-disciplinary industry forums, and high-impact networking events to accelerate cross-border partnerships in Hong...
China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of...
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- Innorna, a clinical-stage biotech company advancing RNA medicines, today announced that it has been nominated for the 2026 Prix Galien USA Best Startup...
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
CRANBURY, N.J. and SUZHOU,China, Aug. 5, 2026 /PRNewswire/ -- Recently, Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA)....
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG"...
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory...
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub
Strategic investment reinforces Europe as a core pillar of GenScript's global R&D and production network, following recent U.S. facility expansion. DELFT, Netherlands, March 12, 2026 /PRNewswire/ -- GenScript announced the official opening of...
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated,...
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore
The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- Pfizer...
Another star technology platform of the Sanyou AI-STAL family
——Introducing Sanyou Mrna Mab innovative antibody generation technology platform SHANGHAI, Dec. 6, 2024 /PRNewswire/ -- With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global...